Wang B, Wang H, Zhao A, et al. - Researchers sought to determine clinicalpathology characteristics, molecular features as well as result of male breast cancer patients who expressed estrogen receptor, progesterone receptor as well as human epidermal growth factor receptor, namely triple-positive male breast cancer (TP-MBC), and their comparison was performed with triple-positive female breast cancer patients (TP-FBC). The Surveillance, Epidemiology, and End Results database was used and propensity score matched analysis was employed. This analysis involved 336 TP-MBC and 33,339 TP-FBC patients. More TP-MBC were staged III or stage IV, vs TP-FBC. Age older than 65-years-old, being black, presence of ductal carcinoma and metastases to lung or bone, all these features were more frequent in TP-MBC. In genomic study, the presence of some notable rare mutations, like ERBB2, ERBB3, RB1, CDK12, FGFR2, IDH1, AGO2, GATA3, was found in TP-MBCs, and some of them are not identified in TP-FBC. A worse survival was seen in TP-MBC compared with TP-FBC, and genomic features differed between two groups. Present understanding of TP-MBC and its management may be insufficient and remain to be explored.